Fig. 4: Molecular tumour features associated with KRAS and TP53 co-mutation status (TCGA-LUAD cohort).
From: KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma
a Association of TMB with co-mutations status. b–e Association of TOP2A mRNA, PD-L1 mRNA, mast cells, and CX3CL1 mRNA with co-mutation status. f Numbers of differentially expressed genes between KRASmut/TP53mut tumours and KRASmut/TP53wt tumours (blue), KRASwt/TP53wt tumours (green), and KRASwt/TP53mut tumours (red). g Heatmap display of the significantly enriched and depleted categories of the GSEA cancer hallmark catalogue in the sets of differentially expressed genes. ↑ = overexpressed genes, ↓ = underexpressed genes
